TruSight Comprehensive (US)

The first US FDA-approved distributable comprehensive genomic profiling (CGP) in vitro diagnostic (IVD) with pan-cancer companion diagnostic (CDx) claims test.

Using the Illumina NextSeq 550Dx, TSO Comprehensive is intended as a CDx test to identify cancer patients with solid tumors who are positive for NTRK1, NTRK2, or NTRK3 gene fusions and cancer patients with non-small cell lung cancer (NSCLC) who are positive for RET gene fusions for treatment in accordance with approved therapeutic labeling.1,2